Ambrisentan

Type: Keyphrase
Name: Ambrisentan
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Two Drugs Better Than 1 for Pulmonary Hypertension

MUNICH — Combining ambrisentan ( Letairis , Gilead Sciences, Inc) and tadalafil ( Cialis , Eli Lilly and Company) reduces the risk for clinical failure in pulmonary arterial hypertension by 50% compared with either drug alone, results from the AMBITION ... [Published American Journal of Public Health - 7 hours ago]
First reported 20 hours ago - Updated 20 hours ago - 1 reports

Sarcoid-Associated Pulmonary Hypertension and Lung Transplant

Cordova FC, D'Alonzo G. Sarcoidosis-associated pulmonary hypertension. Curr Opin Pulm Med 2013;19(5):531–537Battesti JP, Georges R, Basset F, Saumon G. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978;33(1):76–84Głuskowski J, Hawryłkiewicz ... [Published General Medicine eJournal - 20 hours ago]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Gilead Will Continue To Rise

Summary Sovaldi sales will continue to grow as the drug is still recording impressive prescription figures. Increased spending on Sovaldi from state Medicaid Programs and insurers will result in higher sales for Sovaldi. Cheaper version of Sovaldi ... [Published Seeking Alpha - Sep 11 2014]
First reported Sep 09 2014 - Updated Sep 10 2014 - 3 reports

Ambrisentan/tadalafil combo could be PAH standard of care

Gilead Sciences and GlaxoSmithKline have caused a stir at the European Respiratory Society meeting in Munich with very impressive late-stage data on a first-line therapy that combines their pulmonary arterial hypertension treatments.The combined treatment ... [Published Pharma Times - Sep 10 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Glaxo (GSK) Updates on Asthma Candidate Mepolizumab

GlaxoSmithKline ( GSK - Analyst Report ) announced positive data from two pivotal phase III studies (MENSA and SIRIUS) on its asthma candidate, mepolizumab. The data was published in the New England Journal of Medicine (NEJM) as well as presented at ... [Published Zacks.com - Sep 09 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Gilead And GSK's Combination Therapy Meets Primary End-point In PAH Patients

Gilead has announced positive results for its Phase-III AMBITION study, which was commenced in collaboration with GSK to treat patients suffering from Pulmonary Arterial Hypertension (PAH)Page 1 of 2Click Ticker to See live coverageGilead Sciences, Inc. ... [Published Bidness Etc - Sep 09 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

GlaxoSmithKline's Phase IIIb/IV combination trial for hypertension meets primary endpoint

GlaxoSmithKline (GSK) has reported results from the first Phase IIIb/IV trial of the combination therapy of ambrisentan and tadalafil to treat patients with pulmonary arterial hypertension (PAH). ... [Published PBR - News - Sep 09 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 5 reports

Volibris, Adcirca combination shows positive results in pulmonary arterial hypertension

A study investigating the combination of GlaxoSmithKline and Gilead Sciences' Volibris (ambrisentan) and Eli Lilly's Adcirca (tadalafil) in treatment naïve patients with pulmonary arterial hypertension (PAH) met its main goal, the UK drugmaker reported ... [Published FirstWord Pharma - Sep 08 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

What's Going to Be Hot at ERS 2014

MUNICH, Germany — First results from AMBITION, the large pulmonary arterial hypertension trial, will be presented at the European Respiratory Society (ERS) International Congress 2014 , which runs from September 6 to 10.Congress chair Oliver Eickelberg, ... [Published General Medicine eJournal - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Pulmonary Hypertension With COLD and Pulmonary Fibrosis

Simonneau G, Gatzoulis MA, Adatia I, et al . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol Cardiol 2013; 62:34–41.** This study is a summary on the updated classification of pulmonary hypertension from the recent World Conference ... [Published General Medicine eJournal - Aug 28 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Industry up in arms against NPPA for bringing 108 non-scheduled drugs under price control

The pharmaceutical industry in the country is up in arms against the recent notification of the National Pharmaceutical Pricing Authority (NPPA) in which the national drug price regulator has brought prices of 108 non-scheduled formulation packs involving ... [Published PharmaBiz - Jul 15 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Orphan designation: Ambrisentan, for the: Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Quotes

He added, "Importantly, it was backed up by good, robust 6-minute walk data and NT-proBNP data. Everything was going in the right direction."
"The length of time before patients experienced clinical failure was significantly prolonged for those receiving first-line combination compared to monotherapy" GSK said
...whether any of the combinations can match the benefit of steroid inhalers, which he said he prefers to avoid because of systemic adverse effects. "I'm curious whether some of these beta agonist and muscarinic antagonist combinations can hold their own against steroids" he noted

More Content

All (21) | News (17) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Two Drugs Better Than 1 for Pulmonary Hypertension [Published American Journal of Public Health - 7 hours ago]
Sarcoid-Associated Pulmonary Hypertension and L... [Published General Medicine eJournal - 20 hours ago]
Gilead Will Continue To Rise [Published Seeking Alpha - Sep 11 2014]
Ambrisentan/tadalafil combo could be PAH standa... [Published Pharma Times - Sep 10 2014]
GSK and Gileads combination therapy positive re... [Published BioPortfolio - Sep 09 2014]
Glaxo (GSK) Updates on Asthma Candidate Mepoliz... [Published Zacks.com - Sep 09 2014]
Gilead Reports Ambrisentan, Tadalafil Combo Bet... [Published Bioresearch Online - Sep 09 2014]
Gilead And GSK's Combination Therapy Meets Prim... [Published Bidness Etc - Sep 09 2014]
GlaxoSmithKline's Phase IIIb/IV combination tri... [Published PBR - News - Sep 09 2014]
Volibris, Adcirca combination shows positive re... [Published FirstWord Pharma - Sep 08 2014]
GSK Announces Results of Late-Stage PAH Trial W... [Published Nasdaq - Sep 08 2014]
Gilead: AMBITION Study Of Ambrisentan/Tadalafil... [Published RTTNews.com - Sep 08 2014]
First-Line Combination of Ambrisentan and Tadal... [Published Fort Mills Times - Sep 08 2014]
First-Line Combination of Ambrisentan and Tadal... [Published Digital Journal - Sep 08 2014]
First-Line Combination of Ambrisentan and Tadal... [Published Business Wire Health News - Sep 08 2014]
What's Going to Be Hot at ERS 2014 [Published General Medicine eJournal - Aug 29 2014]
Pulmonary Hypertension With COLD and Pulmonary ... [Published General Medicine eJournal - Aug 28 2014]
Industry up in arms against NPPA for bringing 1... [Published PharmaBiz - Jul 15 2014]
Orphan designation: Ambrisentan, for the: Treat... [Published Orphan designations - Jul 10 2014]
Methods of treating mixed dyslipidemia [Published PharmCast - Apr 08 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Mar 27 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
GlaxoSmithKline's Phase IIIb/IV combination tri... [Published PBR - News - Sep 09 2014]
GlaxoSmithKline (GSK) has reported results from the first Phase IIIb/IV trial of the combination therapy of ambrisentan and tadalafil to treat patients with pulmonary arterial hypertension (PAH). ...
First-Line Combination of Ambrisentan and Tadal... [Published Business Wire Health News - Sep 08 2014]
MUNICH--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in patients with pulmonary arterial ...
Orphan designation: Ambrisentan, for the: Treat... [Published Orphan designations - Jul 10 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Mar 27 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.